Early-stage study reveals strong immune response and safety profile for ACI-35.030

Acella and Neuvosyn report positive results for investigational DTE therapy

GM CRDC begins trials to assess real-world effectiveness of respiratory vaccines

CHMP backs AstraZeneca and Amgen’s therapy for chronic rhinosinusitis

EMA opinion supports expanded use of TREMFYA in phase 3 UC treatment

BlueRock begins phase 3 study of bemdaneprocel in Parkinson’s disease

Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU

Preclinical results highlight potential of glycosaminoglycan-based therapy

Data from trials highlight long-term disease control and quality of life improvements